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Abstract  
Aims: We investigated the antidiabetic actions of three dogfish glucagon peptide analogues 
(known GLP-1 and glucagon receptor co-agonists) following chronic administration to diet-
induced high fat fed (HFD) diabetic mice.  Materials and methods: NIH Swiss mice were pre-
conditioned to a HFD (45% fat) for 100 days, or control mice were fed a normal diet (10% fat).  
Normal diet control and HFD control mice received twice daily i.p. saline and HFD groups (n=8) 
received twice daily injections of or exendin-4(1-39), [S2a]dogfish glucagon, [S2a]dogfish 
glucagon exendin-4(31-39) or [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (25 nmol/kg body 
weight) for 51 days.  Results: Following dogfish glucagon analogue treatment, there was a rapid 
and sustained decrease in non-fasting blood glucose and associated insulinotropic effect 
(ANOVA, p<0.05–p<0.001) compared to saline-treated HFD controls.  All peptide treatments 
significantly improved i.p. and oral glucose tolerance with concomitant increased insulin 
secretion compared to saline-treated HFD controls (p<0.05-p<0.001). Following chronic 
treatment, no receptor desensitisation was observed but insulin sensitivity was enhanced for all 
peptide treated groups (p<0.01-p<0.001) except [S2a]dogfish glucagon. Both exendin-4 and 
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[S2a]dogfish glucagon exendin-4(31-39) significantly reduced plasma triglycerides 
concentrations compared to lean controls (p=0.0105 and p=0.0048, respectively).  Pancreatic 
insulin content was not affected by peptide treatments but [S2a]dogfish glucagon and 
[S2a]dogfish glucagon exendin-4(31-39) decreased pancreatic glucagon by 28-34% (p=0.0221 
and p=0.0075, respectively). The percentage β-cell area within islets was increased by exendin-4 
and peptide analogue treatment groups compared with HFD controls and the α-cell area 
decreased (p<0.05-p<0.01).  Conclusions: Overall, dogfish glucagon co-agonist analogues 
demonstrated several beneficial metabolic effects showing therapeutic potential for T2DM. 
 
Keywords: Dogfish glucagon, peptide analogues, chronic study, diabetic mice, co-agonist, 
glucagon like peptide-1, therapy 
 
 
 
 
 
Introduction:  
Glucagon is recognized for its role in preventing hypoglycaemia mainly through 
promoting hepatic glucose output in the fasting state [1], as well as having a pathogenic role in 
diabetes [2]. Thus hyperglycaemia makes an important contribution to elevated blood glucose 
concentrations in both Type 1 and Type 2 diabetes [3,4]. However, under different conditions, 
glucagon has several potentially beneficial extrahepatic actions including, stimulation of insulin 
secretion as well as promoting lipolysis, inhibiting feeding and enhancing energy expenditure [5-
8].   
Research on the use of stable incretin peptides (mimetics) for type 2 diabetes (T2DM) has 
expanded considerably over the past decade [9-11]. Exploitation of the multiple antidiabetic 
actions of GLP-1 have realized benefits including, enhancement of glucose-induced insulin 
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secretion, suppression of pancreatic glucagon secretion and appetite, slowing of postprandial 
gastric emptying, promotion of glucose uptake and possibly protection of pancreatic β-cell mass 
10,12-14].  These benefits of GLP-1 have led to widespread clinical use of incretin mimetics such 
as exenatide (Byetta) and the GLP-1 receptor agonist liraglutide (Victoza) [15-20]. Coupled with 
this, there may be further therapeutic benefits from simultaneous activation of two or more 
receptor signaling pathways for the glucagon-secretin family of peptides, including glucagon, 
GIP as well as CCK-8 [21-23]. This has resulted in a growing interest in the use of dual or triple 
co-agonist peptides which could enhance multiple metabolic pathways and provide better and 
more physiological treatment options [14,21-29].   
 In particular, the simultaneous activation of the glucagon receptor (GCGR) and GLP-1 
receptor (GLP-1R) exerts synergistically superior effects on body weight, glycaemic control and 
lipid metabolism [30-32].  A study by Pocai and colleagues [33] testing GLP-1/glucagon dual-
agonists found that normalisation of glycaemic control, as well as significant weight loss were 
more impressive in diet-induced obese mice treated with the dual agonist compared with a GLP-
1R selective agonist alone.  In another study, GLP-1/glucagon co-agonism improved resting 
energy expenditure in obese mice, and it was inferred that the dual receptor activation would have 
beneficial effects also on glycaemic control and lipid metabolism in humans with T2DM [32].  
 We have a strong interest in examining the potential of peptide entities which have 
structural similarities with incretin hormones and glucagon in an attempt to uncover and test 
novel approaches to diabetes and obesity therapy [14,34-36].  In this regard, we were attracted to 
dogfish glucagon which exhibits strong structural similarities with human GLP-1, GIP and 
glucagon [37]. Comparison of the primary structures also indicates that dogfish glucagon shares 
three amino acid residues (Glu3, Tyr13, and Lys20) with human GLP-1 that are not found in human 
glucagon (Table 1).  This led us to hypothesise that dogfish glucagon may represent a template 
for the design of new antidiabetic peptides that may possess multiple agonist activity.   
We have recently published a manuscript which examined the stability, in vitro 
insulinotropic action and in vivo acute biological activity including glucose lowering and insulin 
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secretory actions, as well as receptor specificity of 13 different analogues of dogfish glucagon 
[38]. From this initial work we wanted to evaluate the chronic metabolic effects of the most 
potent analogues. Thus in the present paper we report the ability of daily treatment with dogfish 
glucagon, a novel enzyme resistant (D-amino acid substitution at position 2) [S2a]dogfish 
glucagon and two sister analogues (modified to prolong their in vivo activities) to alleviate the 
symptoms associated with insulin resistance and Type 2 diabetes in mice resulting from chronic 
consumption of a high fat diet. We have compared the effects of 51 days treatment with these 
peptides with those of exendin-4 on glycaemic control, body weight, food intake, lipid 
metabolism, insulin sensitivity and pancreatic islet morphology in high fat fed DIO mice.  
 
Materials & Methods:  
Synthetic Peptides. Table 1 displays the amino acid sequence of human glucagon, dogfish 
glucagon, GLP-1, GIP and three dogfish glucagon analogues used in this study.  All peptides 
were purchased at >95% purity from EZBiolabs (Carmel, IN, USA).  In addition to QC data 
provided by the supplier, all peptides were checked for purity, characterized and structures 
confirmed using RP-HPLC and in-house matrix assisted laser desorption ionization-time of flight 
mass spectrometry (MALDI-ToF MS), as described previously [39].   
 The basic structure of dogfish glucagon was modified by substitution of D-Ala at the 
penultimate N-terminal residue [S2a] to confer enzyme resistance. In addition, we extended the 
C-terminus of [s2a]dogfish glucagon with the last 9 C-terminal amino acid residues of exendin-
4(1-39) (P-S-S-G-A-P-P-P-S-amide), called [s2a]dogfish glucagon exendin-4(31-39) to help 
stabilize the molecule and improve its ability to interact with the GLP-1 receptor.  Finally, a 
gamma-glutamyl spacer with palmitate adjunct was added at the Lys8 side-chain to [s2a]dogfish 
glucagon to promote albumin binding and extend its in vivo bioactivity as previously reported for 
stable incretin hormone analogues [40,41]. 
 
Animals.  
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Animal studies were carried out using male NIH Swiss TO mice supplied at 8-10 weeks of age by 
Harlan Ltd. (Blackthorne, UK). experimental diabetes was induced by feeding a high-fat diet for 
100 days composed of 45% fat, 20% protein and 35% carbohydrate (total energy 26.15 KJ/g; 
Special Diet Services, Essex, UK).  Control mice were fed normal rodent chow (10% fat, 30% 
protein and 60% carbohydrate, total energy 12.99 KJ/g, Trouw Nutrition, Cheshire, UK). The 
high fat fed group exhibited increased body weight and hyperglycaemia compared with normal 
diet controls (Fig. 1A, 1D). Animals were housed at 22 ± 2°C with a 12 h light: 12 h dark cycle 
(08:00–20:00 h), and had free access to drinking water and food. All animal experiments were 
conducted according to UK Animals (Scientific Procedures) Act 1986 and the “Principles of 
Laboratory Animal Care” (NIH Publication Number 86-23, revised 1985). No adverse effects 
were observed following administration of any of the peptides. 
 
Chronic effect of twice daily i.p. administration of peptides on metabolic status in high fat fed 
mice  
Normal mice and high fat diet fed mice (n=8) received twice daily i.p. injections of saline vehicle 
(0.9% NaCl (w/v)) at 08:30 and 17:30 for up to 65 days. Treatment groups of DIO mice (n=8) 
similarly received twice daily i.p. injections of [S2a]dogfish glucagon, [S2a]dogfish glucagon 
exendin-4(31-39), [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL or exendin-4(1-39) (25 nmol/kg 
body weight).  This dose was based upon responses derived from an earlier acute study [38]. A 
series of metabolic tests were performed (days 51 to 65) and both blood and tissue samples were 
collected at termination of the study (day 65). 
 
Metabolic tests and monitoring  
Food intake, body weight, blood glucose and plasma insulin were monitored at intervals of 2-3 
days. Blood samples for glucose and plasma insulin were collected from the cut tail vein of 
conscious mice. Blood glucose was measured using an Acensia Contour meter (Bayer Healthcare, 
UK). Samples for insulin analysis were collected into chilled fluoride coated microcentrifuge 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
tubes (Sarstedt, Numbrecht, Germany). Blood was centrifuged at 4˚C using a Beckman centrifuge 
for 3 min at 12,000×g and resulting plasma aliquoted into Eppendorf tubes and stored at -20˚C 
prior to determination of insulin by modified dextran coated charcoal radioimmunoassay [42].  
 
Glucose tolerance, insulin sensitivity and peptide desensitisation tests  
Animals were fasted 18 h prior to administration of intraperitoneal or oral glucose alone (18 
mmol/kg body weight) or combined with either a dogfish glucagon analogue or exendin-4 (all at 
25 nmol/kg body weight). Blood samples were collected prior to (t=0) and at 15, 30, 60, 90 and 
120 min post injection. For assessment of insulin sensitivity, blood glucose was measured 
immediately prior to (t=0) and at 15, 30 and 60 min following intraperitoneal administration of 
insulin (25 U/kg body weight). Results obtained provide an estimate of insulin action. 
Unfortunately, we were not able to conduct hyperinsulinaemic euglycaemic clamps in these mice. 
However, mice were assessed for desensitisation to peptide analogues following 51 days chronic 
administration. Glucose (18 mmol/kg body weight, i.p.) was administered alone or in 
combination with the peptide analogues (each at 25 nmol/kg body weight) to 18 h fasted mice. 
Blood samples were collected immediately prior to (t=0) and at 15, 30 and 60 min post injection. 
Blood glucose was assessed immediately using a handheld Acensia Contour glucose meter (Bayer 
Healthcare, UK) and samples for insulin were collected and analysed as described above. Food 
and water were withheld throughout the study periods. All tests were conducted between day 51 
and day 65 with twice daily injection regimens maintained throughout.  
 
Measurement of energy expenditure 
After 60 days, mice were placed in Complete Laboratory Animal Monitoring System (CLAMS) 
metabolic chambers (Columbus Instruments, Columbus, OH, USA) following injection of 
respective peptides at 12:00 h. Consumption of O2 and production of CO2 were measured for 30 s 
at 15 min intervals for a total period of 22 h. Respiratory exchange ratio (RER) was calculated by 
dividing VCO2 by VO2. Energy expenditure was calculated using RER with the following 
equation (3.815 + 1.232 x RER) x VO2 [43].  
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Tissue excision 
 
At the end of the study, non-fasted mice were killed by cervical dislocation. Blood was collected 
by cardiac puncture for determination of glucagon, amylase and lipids. The pancreas from each 
mouse were excised and taken for histology or wrapped in aluminium foil, snap frozen in liquid 
nitrogen with storage at -70˚C for subsequent determination of hormone contents. 
 
Assessment of plasma glucagon, amylase and lipid profile 
Glucagon was measured using an ELISA kit according to the manufacturer’s instructions 
(Millipore, Billerica, Massachusetts, USA). Serum amylase was determined using an amylase 
colorimetric assay kit from Abcam (Cambridge, UK) according to the manufacturer’s 
recommended protocol. Plasma lipid profile was determined using an I-Lab 650 clinical 
chemistry system (Instrumentation Laboratory, Warrington, UK), which included assessment of 
total cholesterol, triglycerides, and both HDL and LDL cholesterol. Reagents for triglycerides 
analysis were obtained from Instrumentation Laboratory (Warrington, UK) and reagents for LDL 
cholesterol were obtained from Randox (Crumlin, Co. Antrim, N. Ireland). 
 
Histological analyses and hormone contents of pancreatic tissue 
Pancreas tissues were fixed in 4% paraformaldehyde for 48 h at 4˚C and then processed using 
automated tissue processor (Leica TP1020, Leica Microsystems, Nussloch, Germany). After 
embedding in paraffin wax, tissues were sectioned at 8 μm thickness using a microtome (Shandon 
finesse 325, Thermo scientific, UK) and sections were picked at an interval of 10 sections. The 
tissue sections were deparaffinised using Histoclear II (National Diagnostics, UK) and rehydrated 
through a series of ethanol. After antigen retrieval at 94˚C for 20 min using citrate buffer (pH 
6.0), the sections were blocked using 10% normal goat serum and incubated with primary 
antibodies overnight at 4˚C. The sections were then incubated with secondary antibodies for 45 
min at 37˚C. The slides were mounted using anti-fade mounting medium and viewed under FITC 
filter (488 nm) or TRITC filter (594 nm) using a fluorescent microscope (an Olympus system 
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microscope, model BX51) and photographed using the DP70 camera adapter system [44,45]. All 
staining procedures and image analysis were carried out in a blinded manner. Approximately 150 
islets were analysed per group. Islet parameters were determined using the ‘closed polygon’ tool 
in Olympus Cell^F analysis software. Antibodies used were highly specific and showed no cross-
reactivity with related peptide hormones. For determination of pancreatic insulin and glucagon 
contents, pancreatic tissue was extracted in 5 ml/g acid ethanol (ethanol/0.7 M HCl; 3:1 ratio) as 
described previously [21]. 
 
Statistical analysis  
Data was analysed using measures of one-way ANOVA followed by a Student Newman-Keuls 
post-hoc test or repeated measures of two tailed t-tests using GraphPad PRISM (Version 5.0 San 
Diego, CA, USA). Data are expressed as mean ± SEM where p<0.05 was considered to be 
statistically significant.   
Results: 
Effect of [S2a]dogfish glucagon, [S2a])dogfish glucagon exendin-4(31-39), [S2a]dogfish 
glucagon-Lys30-γ-glutamyl-PAL or exendin-4 on metabolic status 
There was a rapid and sustained decrease in non-fasting blood glucose in all treatment groups 
(p<0.05–p<0.001), associated with elevated plasma insulin concentrations (P<0.05-p<0.01; Fig. 
1A,B).  Twice daily administration of the peptides had no significant effect on cumulative food 
intake or body weight (Fig.1C,D) or in the % body weight change between experimental groups 
over 51 days (Fig. 1E). A small progressive increase in body weight was observed with saline 
treated high fat fed mice (Fig. 1D).  
 
Glucose tolerance 
Administration of [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39), [S2a] dogfish 
glucagon-Lys30-γ-glutamyl-PAL or exendin-4 for 51 days significantly improved intraperitoneal 
and oral glucose tolerance compared to high-fat fed saline treated control mice (p<0.05 - 
p<0.001) (Fig. 2A,B). Furthermore, there was a significant increase in plasma insulin 
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concentrations were noted over 120 min with all of the treated groups. Importantly, [S2a]dogfish 
glucagon exendin-4(31-39) was the most effective therapy at increasing the overall plasma insulin 
release post i.p. glucose load compared to high-fat fed saline treated controls (p<0.05-p<0.001) 
(Fig. 2A). Similarly, an oral glucose challenge showed very similar responses to those observed 
following the ipGGT described above (Fig 2B). 
 
Effect of dogfish glucagon analogues on peptide desensitization and insulin sensitivity 
Chronic treatment of high-fat fed mice with exendin-4 or dogfish glucagon analogues might lead 
to receptor desensitization and so we tested mice for this type of response. Mice which had been 
exposed to twice daily i.p. injections of these peptides for 51 days were tested.  When given in 
combination with glucose, each of these peptides significantly suppressed the rise in blood 
glucose by 34.8% to 55.2% following i.p. glucose administration (p<0.05-p<0.001) (Fig. 3A). In 
addition, each of the peptides elicited a significant insulin response (1.8- to 2.3-fold increase; 
p<0.05-p<0.001) (Fig. 3B), indicating absence of receptor desensitisation or receptor 
tachyphylaxis.  
 
As shown in Fig. 3C, the glucose lowering effects of insulin were enhanced in all groups 
following chronic peptide administration (Fig. 3C).  Overall insulin sensitivity as assessed by 
integrated area above the curve (AAC(0-120 min)) analysis was enhanced for all peptide treated 
groups (by 13.7% to 21.7%) except for [S2a]dogfish glucagon, compared to saline treated high 
fat fed controls (Fig. 3C).  Indeed, insulin sensitivity of peptide treated mice was similar to that of 
the lean mice fed the normal rodent diet (Fig. 3C). 
 
Effect of dogfish glucagon analogues on circulating lipids, amylase and glucagon concentrations  
The elevated levels of plasma total cholesterol in high fat fed mice (p<0.01) were not reversed by 
administration of [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39), [S2a]dogfish 
glucagon-Lys30-γ-glutamyl-PAL or exendin-4 (Fig 4A).    Peptide treatments did not alter the 
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HDL-cholesterol response in high fat fed mice, except for [S2a]dogfish glucagon exendin-4(31-
39) which reduced the HDL-cholesterol concentrations (Fig. 4B; p=0.0315).  Similarly, the 
peptide treatments failed to counteract the rise in LDL-cholesterol found in high fat fed mice, 
except for the acylated [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL group which exhibited 
similar levels to lean mouse controls (Fig. 4C).  Both exendin-4 and [S2a]dogfish glucagon 
exendin-4(31-39) significantly reduced plasma triglycerides concentrations compared to lean 
controls (Fig. 4D; p=0.0105 and p<0.0048, respectively).   
 
As shown in Fig 5A, circulating amylase concentrations were similar in all groups of mice, 
indicating lack of adverse effect on pancreatic exocrine function and pancreatitis. Plasma 
glucagon was elevated by chronic high fat feeding (Fig. 5B; p<0.01).  This hyperglucagonaemia 
was significantly reduced by treatment with each of the three dogfish glucagon analogues 
(p<0.05-p<0.01) but not by exendin-4 (Fig. 5C).   
 
Effect of dogfish glucagon analogues on pancreatic hormone content and islet morphology  
Saline treated DIO mice had an increased pancreatic insulin and glucagon content (p<0.05) 
compared with mice fed a normal diet (Fig. 5C,D).  Insulin content was not affected by any of the 
peptide treatments (Fig. 5B) but [S2a]dogfish glucagon and [S2a]dogfish glucagon exendin-3(31-
39) decreased pancreatic glucagon by 28-34% ((p=0.0221 and p=0.0075, respectively, Fig. 5D). 
Fig. 6A shows representative images of pancreatic islet morphology in high fat fed mice 
following chronic peptide treatments.  [S2a]dogfish glucagon exendin-4(31-39) caused a small 
reduction in the number of pancreatic islets versus saline treated high fat fed controls (Fig. 6B).  
Smaller islets were also detected in [S2a]dogfish glucagon treated mice (Fig. 6C; p<0.05) which 
might indicate decreased insulin demand due to improved insulin sensitivity.  The percentage 
pancreatic β-cell area within islets was increased by 9.7% to 17.0% in all four peptide treated 
groups compared with high fat fed controls (Fig. 6D; p<0.05-p<0.01) and conversely the peptide 
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treatments led to a reduction in the % α-cell area by 25.9 to 45.5% within islets (Fig. 6E; p<0.05-
p<0.01).   
 
Effect of dogfish glucagon analogues on energy expenditure 
There were no significant changes in oxygen consumption, carbon dioxide production, respiratory 
exchange or energy expenditure following treatment with dogfish glucagon analogues versus 
controls (Supplementary Figs. 1-4).   
 
Discussion: 
Dogfish glucagon has structural similarities to mammalian glucagon (83% sequence homology), 
GLP-1 (55%) and GIP (53%) and as such provides a possible template for development of 
potential multi-acting peptides.  An earlier study in our laboratory has demonstrated that 
[S2a]dogfish glucagon and related analogues can activate both the GLP-1 and glucagon receptors 
without appreciable effects at the GIP receptor [38]. This is an important finding because co-
agonist peptides afford novel therapeutic agents which could be beneficial in combatting the 
growing global health challenge of T2DM, obesity and related metabolic diseases 
[14,22,28,33,46].  
 In the current study, we examined the metabolic effects of twice daily dogfish glucagon 
analogue administration for 51 days in mice that had been pre-conditioned to develop obesity 
related diabetes by feeding a high fat diet [47].  Dogfish glucagon like its mammalian counterpart 
is susceptible to rapid degradation by DPP-4 removing the N-terminal dipeptide His1-Ser2 
producing the truncated fragment glucagon(3-29).  Thus we developed structurally modified 
stable analogues including [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39), 
[S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL [38] to compare with the established therapeutic 
GLP-1 mimetic exendin-4. 
Over the course of the study, we observed a marked and sustained improvement in 
glycaemic control in all peptide treated groups compared to saline treated high fat fed controls.  
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Non fasting blood glucose concentrations were decreased and plasma insulin concentrations 
enhanced. However, no significant changes were noted in food intake despite a small reduction in 
body weight gain in the [S2a]dogfish glucagon, [S2a]dogfish glucagon exendin-4(31-39) and 
[S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL treated groups. This might be related to small 
imbalance between energy intake and expenditure although we failed to demonstrate changes in 
the latter using CLAMS monitoring. Interestingly, other studies in rodents have also failed to 
show benefit of exendin-4 on body weight or food intake [48,49]. 
In contrast, major metabolic benefits were observed in all groups of peptide treated high 
fat fed mice. The improvements in oral and intraperitoneal glucose tolerance, insulin secretion, 
lipid metabolism and insulin sensitivity evident with the [S2a]dogfish glucagon analogues 
correlate well with effects of exendin-4 and other studies which examined metabolic responses to 
oxyntomodulin or dual acting agonists in diet-induced obese mice [21.30,31,33]. In support of 
our findings, these researchers noted improvements in insulin sensitivity and lipid levels which 
were mostly independent of the food intake or a body weight lowering effects [31,33].  Our 
outcomes also correlate well with findings by Finan and colleagues [28] using another dual 
agonist approach activating both GLP-1 and GIP receptors. These results along with good acute 
glucose-lowering and insulin-releasing responses to [S2a]dogfish glucagon peptides in mice 
receiving chronic peptide treatments indicate no loss of bioactivity or receptor tachyphylaxis.  
Furthermore, none of the treatments had adverse effects over 65 days on circulating amylase 
concentrations thereby revealing no indication of possible pancreatitis as reported for GLP-1 
mimetics in some other studies [50-51].  Indeed, exendin-4 and [S2a]dogfish glucagon exendin-
4(31-39) had the additional benefit of decreasing circulating triglycerides. 
Mice fed the high fat diet exhibited characteristic increases in plasma insulin and 
glucagon together with enhanced pancreatic hormone stores. Beta cell area was enhanced 
whereas islet number was unchanged as observed previously [52]. Chronic peptide treatment 
increased plasma insulin without affecting beta cell areas but islet alpha cell areas were decreased 
resulting in significant suppression of islet area with [S2a]dogfish glucagon. Plasma glucagon 
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concentrations were also suppressed suggesting that improvements in blood glucose control were 
due to combined benefits of improved insulin secretion, alpha cell function and insulin 
sensitivity. Overall, the effects of the different dogfish glucagon analogues were broadly similar, 
and longer-term studies might be necessary to reveal benefit of acylation which might be 
expected to impart greater benefit due to more sustained exposure due to albumin binding [53]. 
Further studies are required to explore this aspect including pharmacokinetic studies which are 
currently impossible to undertake due to the need for specific antibodies and assay development. 
From these various metabolic observations, it is clear that dogfish glucagon does not 
operate in mice in a manner analogous to mammalian glucagon which increases plasma glucose 
concentrations.  Indeed, this study and our previous in vitro and acute in vivo studies [38] suggest 
an action profile more similar to oxyntomodulin which is a naturally occurring C-terminally 
extended form of glucagon known to activate both glucagon and GLP-1 receptors [22,43]. 
Interestingly there is a significant difference in the C-terminal structure of these analogues 
compared with oxyntomodulin itself. Earlier work in our laboratory using receptor transfected 
cells and with specific antagonists indeed confirms that dogfish glucagon analogues activated 
both the glucagon and GLP-1 receptors but not the GIP receptor [38]. Furthermore, the peptides 
exhibited antihyperglycaemic and insulinotropic effects in GIP receptor knock-out (GIPR KO) 
mice, whereas these actions were significantly curtailed in mice without functional GLP-1 
receptors [38]. 
Significant evidence has been obtained recently from preclinical studies to support a 
positive role for glucagon acting as a satiety factor, increasing resting energy expenditure and 
promoting lipolysis in adipose tissue [1,4,54].  As highlighted in recent years, GLP-1 has many 
physiological actions which can help ameliorate diabetes, including reduction of food intake, 
slowing of gastric emptying, promotion of glucose uptake in peripheral tissues, inhibition of 
glucagon release and stimulation of glucose-dependent insulin secretion and enhancement of beta 
cell function [13,14].  The results of the present study demonstrated that stable dogfish glucagon 
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analogues can counteract the diabetogenic influence of high fat feeding in mice. The analogues 
are at least as effective as exendin-4 (Byetta) and may provide a possible new unimolecular 
candidate molecule for T2DM treatment by co-agonistic action.   
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Legends to Figures: 
 
Fig. 1  Chronic effect of twice daily administration of exendin-4, [S2a]dogfish glucagon, 
[S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (each 
at 25 nmol/kg body weight) on non-fasting (A) blood glucose, (B) plasma insulin, (C) cumulative 
food intake, (D) body weight and (E) % body weight change in high-fat fed mice during 51 day 
treatment. The black horizontal bar represents the treatment period. Values represent mean ± 
SEM for 8 mice. *p<0.05, **p<0.01 and ***p<0.001 compared to saline treated control. 
 
 
Fig. 2 Effect of twice daily administration of exendin-4, [S2a]dogfish glucagon, [S2a]dogfish 
glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL on blood glucose 
and plasma insulin in response to an intraperitoneal (A,C) and oral (B,D) glucose challenge in 
high-fat diet fed mice. Tests were performed following 51 days of twice daily intraperitoneal 
administration of saline ((0.9% w/v) NaCl), exendin-4 or dogfish glucagon analogues (each at 25 
nmol/kg body weight). Mice were fasted for 10 h previously. Blood glucose (A and B) and 
plasma insulin concentrations (C and D) were measured prior to and after i.p. (A,C) or oral (B,D) 
administration of glucose (18 mmol/kg body weight). Blood glucose and integrated plasma 
insulin response (Area Under the Curve, AUC) are also included. Values represent mean ± SEM 
for 8 mice. *p<0.05, **p<0.01 and ***p<0.001 compared with saline-treated control. 
 
Fig. 3 Effect of twice daily administration of exendin-4, [S2a]dogfish glucagon, [S2a]dogfish 
glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL on blood glucose 
(A) and plasma insulin (B) in response to peptide desensitisation and insulin sensitivity (C) in 
high-fat diet fed mice. Tests were performed following 51 days of twice daily intraperitoneal 
administration of saline ((0.9% w/v) NaCl), exendin-4 or dogfish glucagon analogues (each at 25 
nmol/kg body weight). Blood glucose and plasma insulin concentrations were measured prior to 
and after i.p. administration of each peptide (25 nmol/kg body weight) with glucose (18 mmol/kg 
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body weight) in 10 h fasted mice. For insulin sensitivity, insulin (25 U/kg bw) was administrated 
by i.p. injection to fed mice at t=0 min. Blood glucose and plasma insulin AUC values are also 
included. Values represent mean ± SEM for 8 mice. *p<0.05, **p<0.01 and ***p<0.001 
compared with saline-treated control.        
 
Fig. 4 Effects of twice daily administration of saline, exendin-4, [S2a]dogfish glucagon, 
[S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL PAL 
(each at 25 nmol/kg body weight) on (A) plasma total cholesterol, (B) HDL cholesterol, (C) 
plasma triglycerides and (D) LDL cholesterol and (D) following 65 day treatment of high-fat fed 
and lean control mice. Values are mean ± SEM for n=8. *p<0.05 and **p<0.01 compared with 
saline treated control. +p<0.05 and ++p<0.01 compared with lean mice.    
 
Fig. 5 Effects of twice-daily i.p. administration of saline, exendin-4, [S2a]dogfish glucagon, 
[S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (each 
at 25 nmol/kg body weight) on (A) amylase activity, (B) plasma glucagon, (C) pancreatic insulin 
content and (D) pancreatic glucagon content.  Observations were made following 65 day 
treatment of high fat fed and lean control mice. Values are mean ± SEM for n=8. *p<0.05 and 
**p<0.01 compared with saline treated control. +p<0.05 and ++p<0.01 compared with lean mice.    
  
Fig. 6 Effects of twice-daily i.p. administration of saline, exendin-4, [S2a]dogfish glucagon, 
[S2a]dogfish glucagon-exendin-4(31-39) and [S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL (each 
at 25 nmol/kg body weight) following 65 day administration on (A) islet morphology, (B) 
number of islets, (C) islet area, (D) beta cell area and (E) alpha cell area. Observations were made 
following 65 day treatment of high fat fed and lean control mice. Representative images are 
shown in (A) all at x40 magnification. Values are mean ± SEM for n=8. *p<0.05 and **p<0.01 
compared with saline treated control. +p<0.05 compared with exendin-4 treated group. 
 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
 
 
-3 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54
30
40
50
60
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL
Lean
***
Time (day)
B
o
d
y
 
w
e
i
g
h
t
 
(
g
)
-3 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54
0
5
10
15
20
25
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
*** *** *** ***
****
*
*** *** *** ****** ***
**
***
*
*
****
**
**
**
**
**
**
****** ***
**
***
***
**
***
***
**
***
***
*** ***
*** *** *** *** *** ***
******
***
** ** **
**
***
*
***
*** ***
*** ***
******
****** ***
*** *** ***
*****
Time (day)
B
l
o
o
d
 
g
l
u
c
o
s
e
 
(
m
m
o
l
/
l
)
-3 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54
0
2
4
6
8
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
*
*
**
*
*
*
*
**
*
**
***
*
*
*
**
**
*
*
*
**
*
**
**
**
*
**
**
*
*
* *
*
**
** **
**
*
*
*
*
*
**
**
Time (day)
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
(
n
g
/
m
l
)
0
50
100
150
200
250
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
Time (day)
C
u
m
m
u
l
a
t
i
v
e
 
f
o
o
d
 
i
n
t
a
k
e
 
(
g
)
Figure 1  
 
 
 
  
  
 
 
 
  
  
 
  
 
A 
C D 
B 
E 
-6
-4
-2
0
2
4
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
%
 
B
o
d
y
 
w
e
i
g
h
t
 
c
h
a
n
g
e
50
51
52
53
54
55
56
57
58
59
60
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
0 30 60 90 120
0
10
20
30
Saline
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon
*
**
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Exendin-4
**
**
Lean
* ***
**
*
*
*
***
*
Time (min)
B
l
o
o
d
 
g
l
u
c
o
s
e
 
(
m
m
o
l
/
l
)
0
250
500
750
1000
1250
1500
Saline
Exendin-4
[S2a]dogfish glucagon
***
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
*
***
***
Lean
**
B
l
o
o
d
 
g
l
u
c
o
s
e
 
A
U
C
(
m
m
o
l
/
l
.
m
i
n
)
0 30 60 90 120
0
1
2
3
4
5
6
Saline
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon
*
[S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL
Exendin-4
**
Lean
*
*
*
*
*
*
*
*
*
*
*
*
Time (min)
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
(
m
m
o
l
/
l
)
0
50
100
150
200
250
Saline
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
*
[S2a]dogfish glucagon-Lys30-γ-glutamyl-PAL
Exendin-4
* *
Lean
*
***
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
A
U
C
(
m
m
o
l
/
l
.
m
i
n
)
0
500
1000
1500
Saline
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
*
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Exendin-4
** ****
Lean
**
B
l
o
o
d
 
g
l
u
c
o
s
e
 
A
U
C
(
m
m
o
l
/
l
.
m
i
n
)
0 15 30 45 60 75 90 105 120
0
10
20
30
Saline
Exendin-4
**
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Ly s
30
-γ-glutamy l-PAL
Lean
*
**
**
*
*
*
T ime (m in )
B
l
o
o
d
 
g
l
u
c
o
s
e
 
(
m
m
o
l
/
l
)
0 30 60 90 120
0
1
2
3
4
5
6
Saline
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon
[S2a]dogfish glucagon-Lys
30
-γ-glutamy l-PAL
Exendin-4
**
Lean
*
*
*
* *
*
*
*
**
*
* **
*
T ime (m in)
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
(
m
m
o
l
/
l
)
0
50
100
150
200
250
Saline
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
*
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Exendin-4
*
Lean
* ****
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
A
U
C
(
m
m
o
l
/
l
.
m
i
n
)
Figure 2  
 
 
 
 
  
  
 
 
 
 
   
 
A B 
C D 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
0 30 60 90 120
0
10
20
30
Saline
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon
*
**
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Exendin-4
*****
Lean
* ***
*
***
***
******
***
***
***
***
***
***
***
***
***
***
***
***
***
***
Time (min)
B
l
o
o
d
 
g
l
u
c
o
s
e
 
(
m
m
o
l
/
l
)
0
250
500
750
1000
1250
1500
Saline
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
***
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Exendin-4
***
***
Lean
***
***
B
l
o
o
d
 
g
l
u
c
o
s
e
 
A
U
C
(
m
m
o
l
/
l
.
m
i
n
)
0 30 60 90 120
0
1
2
3
4
5
6
Saline
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon
**
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Exendin-4
**
Lean
*
*
*
*
*
*
* *
*
*
**
**
**
**
**
**
**
**
*
*
Time (min)
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
(
m
m
o
l
/
l
)
0
50
100
150
200
250
Saline
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
**
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Exendin-4
** **
Lean
*
***
P
l
a
s
m
a
 
i
n
s
u
l
i
n
 
A
U
C
(
m
m
o
l
/
l
.
m
i
n
)
0 10 20 30 40 50 60
0
25
50
75
100
Saline
[S2a]dogfish glucagon
Exendin-4
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
**
**
Lean
*** **
*
***
**
** *
****
***
Time (min)
%
 
B
l
o
o
d
 
g
l
u
c
o
s
e
0
1000
2000
3000
4000
Saline
Exendin-4
(D-A2)dogfish glucagon
***
(D-A2)dogfish glucagon exendin
(D-A2)dogfish glucagon-Lys30-γ-glutamyl-PAL
*
***
Lean
**
P
l
a
s
m
a
 
g
l
u
c
o
s
e
 
A
A
C
(
m
m
o
l
/
l
.
m
i
n
)
Figure 3  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
B 
0
2
4
6
8
Lean
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
++
++ ++++
+
P
l
a
s
m
a
 
t
o
t
a
l
 
c
h
o
l
e
s
t
e
r
o
l
(
m
m
o
l
/
l
)
0
1
2
3
4
Lean
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
+ ++
P
l
a
s
m
a
 
t
r
i
g
l
y
c
e
r
i
d
e
s
(
m
m
o
l
/
l
)
0
1
2
3
Lean
Saline
Exendin-4
(D-A2)dogfish glucagon
(D-A2)dogfish glucagon exendin
(D-A2)dogfish glucagon-Lys
30
-γ-glutamyl-PAL
**
*
+++
++ ++
++
H
D
L
 
c
h
o
l
e
s
t
e
r
o
l
(
m
m
o
l
/
l
)
0
1
2
3
Lean
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
*
+ ++
+ +
L
D
L
 
c
h
o
l
e
s
t
e
r
o
l
(
m
m
o
l
/
l
)
Figure 4  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
A 
C 
D 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
0
500
1000
1500
2000
2500
Lean
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
A
m
y
l
a
s
e
 
a
c
t
i
v
i
t
y
(
m
U
/
m
l
)
0
1000
2000
3000
4000
Lean
Saline
Exendin-4
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
*
+
**
P
a
n
c
r
e
a
t
i
c
 
g
l
u
c
a
g
o
n
c
o
n
t
e
n
t
 
(
p
g
/
g
)
B 
C D 
0
2
4
6
8
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
*
+
+
++
++
P
a
n
c
r
e
a
t
i
c
 
i
n
s
u
l
i
n
 
c
o
n
t
e
n
t
(
u
g
/
g
)
Figure 5  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
0.00
0.05
0.10
0.15
0.20
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
++
**** **
*
P
l
a
s
m
a
 
g
l
u
c
a
g
o
n
(
n
g
/
m
l
)
A 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
 
  
Figure 6A  
         Lean                       Saline                              
 
 
     
 
Exendin-4                  [S2a]dogfish     
       glucagon             
 
 
 
[S2a]dogfish glucagon-  [S2a]dogfish glucagon-   
  -exendin-4(31-39)          Lys
30
-γ-glutamyl-PAL      
 
 
 
 
 
 
This article is protected by copyright. All rights reserved.
Ac
c
e
p
t
e
d
 
A
r
t
i
c
l
e
0
10000
20000
30000
40000
50000
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
*+
*
P
a
n
c
r
e
a
t
i
c
 
i
s
l
e
t
 
a
r
e
a
(
µ
µ µ
µ
m
2
)
0.0
0.5
1.0
1.5
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
*
N
u
m
b
e
r
 
o
f
 
i
s
l
e
t
s
 
(
c
o
u
n
t
p
e
r
 
m
m
2
p
a
n
c
r
e
a
s
)
0
20
40
60
80
100
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
* ***
**
*
B
e
t
a
 
c
e
l
l
 
a
r
e
a
(
%
 
o
f
 
i
s
l
e
t
 
a
r
e
a
)
C 
D E 
Figure 6(B-E)  
  
 
 
 
  
 
 
 
 
  
 
 
 
 
 
B 
0
10
20
30
40
Saline
Exendin-4
[S2a]dogfish glucagon
[S2a]dogfish glucagon-exendin-4(31-39)
[S2a]dogfish glucagon-Lys
30
-γ-glutamyl-PAL
Lean
*
**
*
**
*
A
l
p
h
a
 
c
e
l
l
 
a
r
e
a
(
%
 
o
f
 
i
s
l
e
t
 
a
r
e
a
)
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
TABLE 1 Comparison of primary structures dogfish glucagon, dogfish glucagon analogues and related 
peptides together with their theoretical/observed molecular masses. 
Name  Amino acid sequence  Theoretical 
molecular mass 
(Observed molecular 
mass) 
Dogfish glucagon  
(1‐29) 
H S E G T F T S D Y S K Y M D N R R A K D F V Q W L M 
N T 
 
3528.91 
(3528.14) 
[Sa2]dogfish glucagon  ‐  a  ‐  ‐  ‐  ‐ ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐  ‐  ‐   ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐   ‐   ‐  ‐  
‐  ‐ 
3512.91 
(3514.00) 
[S2a] dogfish glucagon‐
exendin‐4(31‐39) 
‐  a  ‐  ‐  ‐  ‐ ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐  ‐  ‐   ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐   ‐   ‐  ‐  
‐  ‐ P S S G A P P P S amide 
4289.77 
(4290.31) 
[S2a] dogfish glucagon‐Lys30‐γ‐
glutamyl‐PAL 
‐  a  ‐  ‐  ‐  ‐ ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐  ‐  ‐   ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐   ‐   ‐  ‐  
‐  ‐ K‐γ‐Glutamyl–PAL 
4008.65 
(4009.08) 
Human glucagon  ‐  ‐  Q ‐  ‐  ‐ ‐  ‐  ‐  ‐  ‐  ‐  ‐   ‐  L  ‐  S  ‐  ‐  ‐  Q ‐  ‐   ‐   ‐   ‐  ‐  
‐  ‐ 
3482.80 
(3481.49) 
Exendin‐4  ‐  G ‐  ‐  ‐  ‐ ‐  ‐  ‐  ‐  L ‐  ‐  Q  ‐  E  E E A V R  L ‐     E   ‐  ‐   
‐  ‐ P S S G A P P P S amide 
4186.57 
(4186.32) 
GLP‐1(7‐36) amide  ‐  A ‐  ‐  ‐  ‐  ‐  ‐  ‐ V ‐  S  ‐  L  E G Q A ‐  ‐  E ‐    A  ‐   ‐ V  
K G R amide 
3297.70 
(3296.03) 
GIP(1‐30)  Y A ‐  ‐   ‐  ‐   ‐  ‐  ‐  ‐  A  ‐  ‐   K   H Q Q‐  ‐  ‐  N  ‐  ‐  L   
A Q K 
3551.1 
(3550.9) 
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